In severe asthma, Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) reduces exacerbations and improves lung function and quality of life across phenotypes, including those with low eosinophil counts or nonallergic disease [2]. This evidence concerns the gene TSLP and asthma.